カテゴリ： GlobalData, アメリカ, 企業調査

Onconova Therapeutics Inc (ONTX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Onconova Therapeutics Inc (ONTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9796
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：77
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Onconova Therapeutics Inc (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib, briciclib and recilisib. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partners with biopharmaceutical companies and medical organizations in the US. The company operates through its offices in Newtown and Pennington, the US. Onconova is headquartered in Newtown, Pennsylvania, the US.

Onconova Therapeutics Inc (ONTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Onconova Therapeutics Raises US$50 Million In Venture Financing 11
Onconova Therapeutics Raises US$26.4 Million In Venture Financing Round 12
Partnerships 13
Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 13
Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 14
Onconova Therapeutics Enters into Research Partnership with SymBio Pharma 15
GVK Biosciences Enters Into Agreement With Onconova Therapeutics To Develop New Cancer Drugs 16
Licensing Agreements 17
Pint Pharma Enters into Licensing Agreement with Onconova Therapeutics 17
HanX Biopharma Enters into Licensing Agreement with Onconova Therapeutics 18
Baxter International Enters into Licensing Agreement with Onconova Therapeutics 19
Equity Offering 20
Onconova Therapeutics Raises USD28.7 Million Public Offering of Shares and Warrants 20
Onconova Therapeutics Raises USD1.3 Million in Private Placement of Shares 22
Onconova Therapeutics Raises USD10 Million in Public Offering of Shares 23
Onconova Therapeutics Raises USD1.4 Million in Private Placement of Shares 25
Onconova Therapeutics Plans to Raise up to USD84.5 Million in Public Offering of Shares 26
Onconova Therapeutics Raises USD5.2 Million in Public Offering of Shares 27
Onconova Therapeutics Raises USD17.5 Million in Rights Offering of Units 28
Onconova Therapeutics Raises USD1.8 Million in Private Placement of Shares 30
Onconova Therapeutics Raises USD1.5 Million in Private Placement of Shares 31
Onconova Therapeutics Completes IPO Of Shares For US$89 Million 32
Onconova Therapeutics Inc – Key Competitors 34
Onconova Therapeutics Inc – Key Employees 35
Onconova Therapeutics Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 14, 2018: Onconova Therapeutics reports business highlights and financial results for second quarter 2018 37
May 15, 2018: Onconova Therapeutics Reports Business Highlights and Financial Results for First Quarter 2018 39
Mar 08, 2018: Onconova Therapeutics Reports Business Highlights and Full Year 2017 Financial Results 40
Nov 09, 2017: Onconova Therapeutics Reports Third Quarter 2017 Financial Results 42
Aug 15, 2017: Onconova Therapeutics Reports Recent Business Highlights and Second Quarter 2017 Financial Results 43
May 15, 2017: Onconova Therapeutics Reports Recent Business Highlights and First Quarter 2017 Financial Results 45
Mar 27, 2017: Onconova Therapeutics Reports Recent Business Highlights and Year-end 2016 Financial Results 47
Corporate Communications 48
Nov 07, 2018: Onconova welcomes Richard Woodman, M.D., as Chief Medical Officer 48
Jun 21, 2018: Onconova Therapeutics Promotes Steven M. Fruchtman To President 49
Product News 50
11/15/2017: Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia 50
07/25/2017: Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies” 52
02/20/2018: Onconova Announces Presentation on its Acute Myeloid Leukemia Drug Candidate ON-150030 at 2018 American Chemical Society National Meeting and Expo 53
02/02/2018: Onconova Announces Presentation Of Mechanism Of Action Studies Of Rigosertib Combination With Azacitidine At American Association For Cancer Epigenetics Research Conference 54
Clinical Trials 55
Jan 17, 2018: Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis 55
Dec 12, 2017: Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Meeting 57
Nov 16, 2017: Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting 59
Nov 09, 2017: Onconova Therapeutics Provides Update on Rigosertib 61
Nov 01, 2017: Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting 64
Oct 10, 2017: Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 65
Oct 04, 2017: Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City 66
Jun 30, 2017: SymBio Pharmaceuticals Announces Initiation in Japan of the Phase I Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 67
Jun 26, 2017: Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid 68
Jun 05, 2017: Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting 70
May 22, 2017: Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association 72
May 18, 2017: Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting 74
May 01, 2017: Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes 75
Apr 04, 2017: Onconova Therapeutics Announces Positive Preclinical Data on ON dual FLT3 and Src inhibitor 150030 at 2017 American Association of Cancer Research Annual Meeting 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Onconova Therapeutics Raises US$50 Million In Venture Financing 11
Onconova Therapeutics Raises US$26.4 Million In Venture Financing Round 12
Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 13
Cellectar Biosciences Enters into Agreement with Onconova Therapeutics 14
Onconova Therapeutics Enters into Research Partnership with SymBio Pharma 15
GVK Biosciences Enters Into Agreement With Onconova Therapeutics To Develop New Cancer Drugs 16
Pint Pharma Enters into Licensing Agreement with Onconova Therapeutics 17
HanX Biopharma Enters into Licensing Agreement with Onconova Therapeutics 18
Baxter International Enters into Licensing Agreement with Onconova Therapeutics 19
Onconova Therapeutics Raises USD28.7 Million Public Offering of Shares and Warrants 20
Onconova Therapeutics Raises USD1.3 Million in Private Placement of Shares 22
Onconova Therapeutics Raises USD10 Million in Public Offering of Shares 23
Onconova Therapeutics Raises USD1.4 Million in Private Placement of Shares 25
Onconova Therapeutics Plans to Raise up to USD84.5 Million in Public Offering of Shares 26
Onconova Therapeutics Raises USD5.2 Million in Public Offering of Shares 27
Onconova Therapeutics Raises USD17.5 Million in Rights Offering of Units 28
Onconova Therapeutics Raises USD1.8 Million in Private Placement of Shares 30
Onconova Therapeutics Raises USD1.5 Million in Private Placement of Shares 31
Onconova Therapeutics Completes IPO Of Shares For US$89 Million 32
Onconova Therapeutics Inc, Key Competitors 34
Onconova Therapeutics Inc, Key Employees 35
Onconova Therapeutics Inc, Subsidiaries 36

List of Figures
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Onconova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Onconova Therapeutics Inc (ONTX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Alarko Contracting Group
    Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report Summary Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Raiffeisen Bank International AG：企業の戦略・SWOT・財務情報
    Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report Summary Raiffeisen Bank International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • AstraZeneca PLC：企業のM&A・事業提携・投資動向
    AstraZeneca PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's AstraZeneca PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Petra Energy Bhd (PENERGY)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petra Energy Bhd (Petra Energy) is an integrated brown field service provider for the upstream oil and gas industry. The company offers services such as designing, procurement, engineering, installation, fabrication, commissioning, maintenance, construction and project management. It also pr …
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.：企業のM&A・事業提携・投資動向
    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descript …
  • Genoptix Inc：医療機器：M&Aディール及び事業提携情報
    Summary Genoptix Inc (Genoptix) is a hematopathology center which provides oncology diagnostics and informatics services specializing in hematology and solid tumors. The center offers biopharma and healthcare laboratory, discovery, drug development, care and cost development, and patient services. G …
  • Aalborg Portland Holding A/S：企業の戦略・SWOT・財務情報
    Aalborg Portland Holding A/S - Strategy, SWOT and Corporate Finance Report Summary Aalborg Portland Holding A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Synergy：企業の戦略・SWOT・財務分析
    Synergy - Strategy, SWOT and Corporate Finance Report Summary Synergy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • AtriCure Inc (ATRC)：医療機器：M&Aディール及び事業提携情報
    Summary AtriCure, Inc. (AtriCure) is a provider of medical devices for the treatment of atrial fibrillation (Afib) and related conditions. The company carries out the development, manufacture and sale of cardiac surgical ablation devices. Its major products include Isolator Synergy ablation system, …
  • Verizon Communications Inc (VZ)：企業の財務・戦略的SWOT分析
    Verizon Communications Inc (VZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • China Aviation Oil (Singapore) Corporation Ltd (G92)：企業の財務・戦略的SWOT分析
    China Aviation Oil (Singapore) Corporation Ltd (G92) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Koch Enterprises, Inc.：企業の戦略的SWOT分析
    Koch Enterprises, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Hengeler Mueller Partnerschaft von Rechtsanwalten mbB：企業の戦略的SWOT分析
    Hengeler Mueller Partnerschaft von Rechtsanwalten mbB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key com …
  • Seelos Therapeutics, Inc. (SEEL)：企業の財務・戦略的SWOT分析
    Seelos Therapeutics, Inc. (SEEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Censa Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Censa Pharmaceuticals Inc (Censa Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for the treatment of rare central nervous system (CNS) disorders. The company provides product pipeline such as therapies for the treatment of extremely rare disorders …
  • Bionomics Ltd (BNO)：企業の財務・戦略的SWOT分析
    Summary Bionomics Ltd (Bionomics) is a biopharmaceutical company that discovers and develops treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer's disease. The company provides pipeline products such as BNC210, BNC 105, BNC101 and BNC375, among other …
  • West Pharmaceutical Services Inc (WST)：企業の財務・戦略的SWOT分析
    West Pharmaceutical Services Inc (WST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Realty Income Corporation：企業のM&A・事業提携・投資動向
    Realty Income Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Realty Income Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Alliance Data Systems Corporation：企業の戦略・SWOT・財務分析
    Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report Summary Alliance Data Systems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Transport for London：企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆